This report on ADME/Tox Technologies gives a market insight into products and services used in the ADME/Tox industry. Predictive technologies analyzed include In vivo, In vitro, and In silico. Related technologies such as High Throughput Screening (HTS), Laboratory Information Management System (LIMS), and cell based assays are also analyzed. Market projections and estimates are illustrated by region and by technology. The report serves as a guide to ADME/Tox industry, covering more than 500 companies that are engaged in ADME/Tox studies/screening, products and services. Major Contract Research Organizations, Research Institutes and Universities serving the ADME/Tox industry are also covered in the corporate directory section of this report. Information related to recent product releases, product developments, partnerships, collaborations, and mergers and acquisitions is covered in the report. Compilation of Worldwide Patents related to ADME/Tox Technologies is also provided. A global perspective is presented along with regional analysis covering the regions of North America, Europe, Asia-Pacific, Latin America, the Middle East and Africa with 97 exclusive graphically represented exhibits.
Table of Content 1. SCOPE AND METHODOLOGY 1 2. REPORT SYNOPSIS 4 ADME/Tox Technologies 4 Absorption 4 Distribution 4 Metabolism 4 Excretion 5 Toxicity 5 2.2 Significant Methods for ADME/Tox 5 Predictive Technologies 5 Related ADME/Tox Methods 5 2.3 ADME/Tox Technologies – Global Market Analysis 6 Exhibit 1. ADME/Tox Technologies – Global Market Estimations and Predictions (2005-2020) in US$ Billion 6 Exhibit 2. Major Global Companies in ADME/TOX Technologies Market 7 3. MARKET DYNAMICS 9 3.1 Market Overview 9 3.2. ADME/Tox Technologies Market 10 Global ADME/Tox Market Analysis 10 Exhibit 3. ADME/Tox Technologies – Global Market Estimations and Predictions (2005-2020) for North America, Europe, Asia-Pacific, and Rest of World in US$ Million 11 Exhibit 4. ADME/Tox Technologies – Global Market Shares (2010, 2015 & 2020) North America, Europe, Asia-Pacific, and Rest of World 12 3.3 North American ADME/Tox Market Analysis 13 Exhibit 5. ADME/Tox Technologies – North American Market Estimations and Predictions (2005-2020) for United States and Canada in US$ Million 13 Exhibit 6. ADME/Tox Technologies – North American Market Shares (20010, 2015 & 2020) for United States and Canada 14 3.3 (1) United States ADME/Tox Market 14 US Market Analysis 14 3.3 (II) Canadian ADME/Tox Market 14 Exhibit 7. List of Major ADME/Tox Companies in North America 15 3.4 European ADME/Tox Market Analysis 16 Exhibit 8. ADME/Tox Technologies – European Market Estimations and Predictions (2005-2020) for UK, Germany, France, Sweden, Finland, Italy, Russia and Rest of Europe in US$ Million 16 Exhibit 9. ADME/Tox Technologies – European Market Shares (2010, 2015 & 2020) for UK, Germany, France, Sweden, Finland, Italy, Russia and Rest of Europe 17 3.3 (1) United Kingdom ADME/Tox Market 17 UK Market Analysis 17 Major Companies in UK ADME/Tox Technologies Market 17 3.4 (II) German ADME/Tox Market 18 German Market Analysis 18 Major Companies in German ADME/Tox Technologies Market 18 3.4 (III) French ADME/Tox Market 18 French Market Analysis 18 Major Companies in French ADME/Tox Technologies Market 18 3.4 (IV) Swedish ADME/Tox Market 18 Swedish Market Analysis 18 3.4 (V) Finnish ADME/Tox Market 18 Finnish Market Analysis 18 3.4 (VI) Italian ADME/Tox Market 19 Italian Market Analysis 19 Major Companies in Italian ADME/Tox Technologies Market 19 3.4 (VII) Russian ADME/Tox Market 19 Analysis by Select Rest of Europe Countries 20 Exhibit 10. ADME/Tox Technologies – Rest of Europe Market Estimations and Predictions (2005-2020) for Switzerland, Hungary, Belgium, Austria, Spain, and Other European Countries in US$ Million 20 Exhibit 11. ADME/Tox Technologies – Rest of Europe Market Share (2010, 2015 & 2020) for Switzerland, Hungary, Belgium, Austria, Spain, and Other European Countries 21 Exhibit 12. List of Major ADME/Tox Companies in Europe 21 3.5 Asia-Pacific ADME/Tox Market Analysis 22 Exhibit 13. ADME/Tox Technologies – Asia-Pacific Market Estimations and Predictions (2005-2020) for Japan, China, India, Australia, South Korea and Rest of Asia-Pacific in US$ Million 23 Exhibit 14. ADME/Tox Technologies – Asia-Pacific Market Shares (2010, 2015 & 2020) for Japan, China, India, Australia, South Korea and Rest of Asia-Pacific 24 3.5 (I) Japanese ADME/Tox Market 24 Japanese Market Analysis 24 Major Companies in Japanese ADME/Tox Technologies Market 24 3.5 (II) Chinese ADME/Tox Market 24 Chinese Market Analysis 24 Major Companies in Chinese ADME/Tox Technologies Market 25 3.5 (III) Indian ADME/Tox Market 25 Major Companies in Indian ADME/Tox Technologies Market 25 3.5 (IV) Australian ADME/Tox Market 25 3.5 (V) South Korean ADME/Tox Market 26 3.5 (VI) Rest of Asia-Pacific ADME/Tox Market 26 Analysis by Select Rest of Asia-Pacific Countries 27 Exhibit 15. ADME/Tox Technologies – Rest of Asia-Pacific Market Estimations and Predictions (2005-2020) for Singapore, Hong Kong and Other Asia-Pacific Countries in US$ Million 27 Exhibit 16. ADME/Tox Technologies – Rest of Asia-Pacific Market Shares (2010, 2015 & 2020) for Singapore, Hong Kong, and Other Asia-Pacific Countries 28 Exhibit 17. List of Major ADME/Tox Companies in Asia-Pacific 28 3.6 Rest of World ADME/Tox Market Analysis 29 Exhibit 18. ADME/Tox Technologies – Rest of World Market Estimations and Predictions (2005-2020) for Brazil, South Africa, Israel and Other Countries in US$ Million 29 Exhibit 19. ADME/Tox Technologies – Rest of World Market Shares (2010,2015 & 2015) for Brazil, South Africa, Israel and Other Countries 30 Latin America 31 A few CROs operating in the Latin American Region 31 Brazilian ADME/Tox Market 31 South African ADME/Tox Market 31 Middle East 32 Israeli ADME/Tox Market 32 Exhibit 20. List of Major ADME/Tox Companies in Rest of World 32 3.7 Company Profiles - Major Players in ADME/Tox Market 33 AB Sciex (USA) 33 Accelrys, Inc. (USA) 34 Advanced Chemistry Development, Inc. (ACD Labs) (Canada) 37 Agilent Technologies, Inc. (USA) 40 Albany Molecular Research, Inc. (USA) 41 Bayer Technology Services GmbH (Germany) 42 BioFocus DPI Ltd. (UK) 43 Bio-Rad Laboratories, Inc. (USA) 44 BioreclamationIVT (USA) 48 Cellectics bioresearch (France) 50 Cerep SA (France) 51 Certara LP (USA) 53 Simcyp Ltd. (UK) 53 Tripos, Inc. (USA) 55 Charles River Laboratories International, Inc. (USA) 55 ChemSilico LLC (The) (USA) 56 Chenomx, Inc. (Canada) 57 CompuDrug International, Inc. (USA) 58 Corning, Inc. (USA) 61 Cyprotex plc (UK) 63 EMD Millipore (USA) 66 GE Healthcare Life Sciences (UK) 66 Gene Logic, Inc. (USA) 68 GenPharmTox BioTech AG (Germany) 69 Harlan Laboratories, Inc. (USA) 72 ID Business Solutions Ltd. (UK) 75 Kibron, Inc. (Finland) 76 Korea Institute of Toxicology (South Korea) 77 LHASA Ltd. (UK) 78 Life Technologies Corporation (USA) 79 Molecular Discovery Ltd. (UK) 80 MultiCASE, Inc. (USA) 82 Perkin Elmer, Inc. (USA) 83 Pharmaron (USA) 85 Promega Corporation (USA) 86 Schrodinger LLC (USA) 86 Sekisui Medical Co., Ltd. (Japan) 87 Simulations Plus, Inc. (USA) 88 Sirius Analytical Instruments Ltd. (UK) 89 Sovicell GmbH (Germany) 89 Strand Life Sciences (India) 91 Taconic Farms, Inc. (USA) 91 Tecan AG (Switzerland) 93 TetraQ (Australia) 93 Thermo Fisher Scientific, Inc. (USA) 94 Waters Corporation (USA) 96 WuXi AppTec Co., Ltd. (China) 97 Xceleron Ltd. (UK) 98 3.8 Major Activities in ADME/Tox Market 99 Charles River Laboratories Acquires the CRO Services Division of Galapagos NV 99 Simulations Plus Inks a 5-year RAC with US FDA 99 Taconic Enters into Collaboration with IVAL 99 Simulations Plus Inks a Supply Agreement with China based RILD 100 Harlan Contract Research Services and Bertin Pharma Enters into Strategic Collaboration Agreement 100 Pharmaron Gains CFDA GLP Certification for Toxicology Facility 100 Thermo Fisher Acquires Life Technologies 100 Cyprotex Acquires Business and Assets of CeeTox 101 Harlan Laboratories Plans to Locate Research Model Breeding Facility in India 101 WuXi PharmaTech Gains ADMET Predictor License 101 Taconic Signs Contract with Medicyte 101 Simulations Plus Inks Alliance with Bayer HealthCare for Improving Key Property Prediction in ADMET Predictor™ 102 Bioreclamation Establishes BioreclamationIVT 102 Simulations Plus Inks MTA with NIEHS 103 AMRI and Ono Expands SMARTSOURCING™ Collaboration 103 VistaGen Therapeutics and Celsis Enter into an Alliance to Develop LiverSafe 3D 103 Calvert Labs and Particle Sciences Form Strategic Alliance to Streamline Early-Stage Drug Development 104 Xceleron Plans to Expand its Access to Powerful Analytical Platforms by Signing Partnership with JCL Bioassay 104 BD Takes Over Cato Software Solutions 104 Agilent Technologies Collaborates with Florida International University for Identification and Characterization of Designer Drugs 105 Lhasa Limited Collaborates with Optibrium 105 Mispro Biotech Services Enters into a Collaboration with The Hamner Institutes for Health Sciences 105 Hamner Institutes Enters into Association with QPS Holdings LLC 106 Accelrys ELN to Collaborate with Reaxys 106 Vivo Bio Signs Supply Agreement with Taconic for the Indian Market 107 Taconic Signs a Strategic Marketing Agreement with Yecuris 107 Charles River Laboratories Acquires Majority Ownership of Vital River 107 GVK BIO Signs Research Deal with Endo Pharmaceuticals 108 Xceleron Collaborates with Crystal Pharmatech for Advancing Early Clinical Development Employing Absolute Bioavailability Trials and Solid-State formulations 108 Elsevier Takes Over Aureus Sciences 108 Accelyrs Acquires its Partner Vialis AG 109 Charles River Takes Overs Vital River 109 Amgen is Working to Build Ultramodern Manufacturing Unit in Singapore 109 Amgen Acquires deCODE Genetics 110 Covance Receives SFDA GLP Certification for Its Early Development Facility in Shanghai, China 110 ShangPharma Corporation Inks a Definitive Merger Agreement facilitating Private Transaction 110 Medicilon Inks Alliance with Xuantai Medical 110 HitGen Enters into Strategic Partnership Agreement with Viva Biotech 111 DiscoveRx Corporation Buys BioSeek 111 NanoViricides Enters into Agreement with BASi for Toxicology and Safety Studies 112 ATTAGENE Receives New US$ 53.4 Million Contract by EPA 112 Simcyp Collaborates with US FDA 112 Corning Acquires Discovery Labware Business of BD 113 TAKEDA Inks a 3-year Drug Discovery Collaboration Agreement with ADVINUS 113 Intellect Neurosciences and iNovacia Signs Research Service Agreement 114 Charles River Laboratories and AstraZeneca Enter Strategic Partnership 114 Gentronix Signs Contract with Kowa for its First Screening Contract in Japan 114 AMRI publicizes agreement with Knopp Biosciences 114 Sigma® Life Sciences and Axiogenesis Collaborate to Market More Predictive iPSC-based Assays and Services for Preclinical Cardiotoxicity Screening 115 COARE Biotechnology and ChemDiv Enters into Co-marketing and Service Collaboration 115 BGI, GE Healthcare Collaborates on Initiating Stem Cell Science Projects 115 Affymetrix Takes Over eBioscience Holding Company, Inc. 116 Sygnature Discovery Enters into Strategic Alliance with Pneumolabs 116 ACD/Labs, Now an Associate Partner of Open PHACTS Project 116 AAIPharma Buys Celsis Analytical 117 Enamine Enters into a Partnership Agreement with UORSY 117 Luminex Corporation Extends its Life Science and Biodefense Units 118 AB SCIEX Sings New Distribution Agreement with Cluster in Serbia and Macedonia 118 AB SCIEX Extends its Business Operations in Brazil 119 Simulations Plus Buys Software Royalty Agreement with New York based Enslein Research 119 BioFocus and Argenta Enters into a Drug Discovery Collaboration Agreement with AstraZeneca 119 Jubilant Inks Drug Discovery Collaboration Agreement with Mnemosyne Pharmaceuticals 119 Covance and BioPontis Alliance Enters into Collaboration to Bridge Drug Development Gap 120 Lhasa Extends Support for “MIP-DILI” 120 Certara Acquires Simcyp 120 Lhasa Limited Inks another RCA with the FDA 121 AB SCIEX and Indigo in Collaboration to Accelerate Adoption of Next-generation Mass Spectrometry for Clinical Research, Forensic Toxicology and Clinical Trials 121 Kyorin Teams Up with BioLeap to Develop New Drug Candidates 121 NiKem Research Enters into a Strategic Partnership Agreement with Dualsystems Biotech 122 Cresset Signs a Technology Exchange Agreement with Optibrium for Enhancing Respective Drug Discovery Solutions 122 Tecan and Waters in OEM Agreement 123 ReproCell In-Licenses hIPSC-Derived Hepatocyte Screening Platform 123 Sygnature Collaborates with Cyprotex 123 Sygnature Discovery and Cyprotex Extend Successful Strategic Alliance for a Further Two Years 123 Gentronix Enters into Partnership with BioQuanta 124 Battelle in Collaboration with Molecular Imaging Enhances Drug Discovery & Development Services 124 Sygnature Discovery Join Forces with Saretius Associate to Offer Drug Discovery and Preclinical Testing Services 124 EMD Millipore to Distribute Cryopreserved HepaRG™ Terminally Differentiated Human Hepatic Cells of Biopredic 124 PerkinElmer Acquires Caliper Life Sciences 125 AB SCIEX Acquires Mass Spectrometry Division of Labindia to Expand its Presence in India 125 Cellectis Acquires Cellartis 125 ShangPharma Takes Over Shanghai In-Vivo Drug Research Facility from Charles River 126 Jubilant Biosys and Norgine to Collaborate for Finding New Drugs to Treat Gastrointestinal Diseases 126 Teva Acquires Cephalon 127 BioFocus Signs a Second Collaboration Agreement with Chiesi 127 Accelrys Collaborates with the Edge Software Consultancy 127 WuXi PharmaTech Acquires Abgent, a Major Manufacturer of Biological Research Reagents 128 GVK Biosciences Extends GOSTAR License to Astellas 128 Hamner Institutes of Health and Virginia based Investment Group Forms JV 128 Absorption Systems Collaborates with Researchers to Improve in Vitro Prediction of Pharmacokinetics 128 Alkermes Acquires Elan’s Drug Technology Business 129 ICON Signs a Contract with Bristol-Myers 129 Genentech and Argenta extend Drug Discovery Contract 129 Argenta and BioFocus Extend Drug Discovery Partnership with Genentech 130 BioFocus Collaborates with Michael J. Fox Foundation for Diagnostics for Parkinson Disease 130 Harvard Bioscience Acquires Eirus Medical, the preclinical business division of CMA 130 BioFocus Expands its Association with Usher III Initiative 130 Midas Intensifies Research Collaboration with CDI 131 Novus Biologicals Partners with Genego 131 Ricerca Biosciences Enters into Partnership with Fulcrum Pharma 131 Agilent Acquires Biocius and Lab901 132 Optiva Enters into Agreement with the US FDA to Provide Transporter Assay Services 133 QPS Acquires DCB Taiwan’s Preclinical Unit 133 Hengdu Frontier BioSciences Selects Pristima for Preclinical Data Management 134 AMRI Consolidates Global Drug Discovery Platform 134 Aureus Pharma Renamed Aureus Sciences; Launches Drug Discovery Web Portal 134 QPS Acquires India based Bioserve for Expansion Of Phase 1 and Bioanalytical Capability 135 Simulations Joins with FDA for Developing Predictive Toxicity Models 135 SRI Incorporates Subsidiary Company Sarnoff 136 BIOCIUS Life Sciences Expands Contract Research Service with New ADME Assay Analysis 136 Entelos Obtains Patent for Predictive Toxicology for Biological Systems 136 PPD and Taijitu Biologics Establishes Joint Venture for Drug Discovery of Large Molecules 137 PAREXEL and Merck in Collaboration for Clinical Development of Bio-Similar Candidates 137 Ligand Takes Over CyDex Pharmaceuticals 138 Ligand and Chiva in Strategic Drug Development Collaboration 138 ICON Buys Oxford Outcomes 138 Dow AgroSciences Partners with GVK Bio to Discover a New Lead Molecule 139 Entelos Receives Patent for Predictive Toxicology for Biological Systems 139 Ecron Acunova Signs MoU with Newcastle University 139 QIAGEN Establishes Indian Subsidiary 140 Taconic Enters Scientific Development Collaboration with BioPontis around Genetically Modified Models for Translational Research 140 Amgen and BioFocus Extends Contract until 2012 140 ADVANCELL Enters into Partnership Agreement with Gentronix 141 Vernalis Enters into Drug Discovery Collaboration with Lundbeck 141 UCSF and Pfizer in Collaboration to Improve Drug Discovery, Development 141 Selcia and Gilead Sciences Extend Liver Disease Drug Discovery Collaboration 142 Selcia in Drug Discovery Collaboration with Convergence Pharmaceuticals for Chronic Pain 142 Thomson Reuters Takes Over GENEGO 142 Life Technologies Inks Agreement with Biopredic for Generating Hepatic Cell Line 143 ACD/Labs and FDA in Development Collaboration for Predictive QSAR Models 143 Optivia and UCSF in Collaboration to Predict Liver Toxicity of Drugs in Development 143 Genstruct Adopts New Corporate Identity and Introduces a Re-branded Website 144 LGC Standards Incorporates Gentronix GreenScreen HC and BlueScreen HC to the company’s Product Portfolio 145 Southern Research Acquires BioCryst Bioanalytical Lab Unit 145 MDS Inc. Renamed Nordion Inc., 145 Cerep and Roche Extends BioPrint® Collaboration 145 Valeant Merges with Biovail Corp 146 Evotec Completes Acquisition of DeveloGen 146 BioFocus and Usher III Initiative, Inc. in Drug Discovery Collaboration 146 AB Sciex Collaborates with the University of Melbourne for Development of Innovative Method for Drug Metabolism Studies of Biopharmaceuticals 146 The Defense Threat Reduction Agency Awards Contract to Numerate for Expansion of Drug Design Platform 147 Cyprotex Buys Stake in Apredica for Widening Services in Toxicology Market 147 NoAb BioDiscoveries and VigiCell Signs an Association and Co-Distribution Contract 148 PerkinElmer Takes Over VisEn Medical to Reinforce Cellular Imaging Service Offerings 148 Entelos Receives US Patent for Validation of Virtual Patients in a Computer Model 149 BioFocus and University of Bristol in Drug Discovery Collaboration for Chronic Pain 149 Charles River Terminates Acquisition Agreement with WuXi PharmaTech 149 AstraZeneca Consents to Drug Discovery Alliance with MRC 150 PPD and Lovelace Biomedical and Environmental Research Institute (LBERI) to Provide Laboratory, Preclinical and Clinical Research Services in Collaboration 150 LAB Research in Preferred Provider Agreement with Leading Japanese Pharmaceutical Company 150 Aptuit and Siena Biotech Enter Strategic Partnership 151 Accelrys and Symyx Technologies Completes Merger to Create Leading Scientific Informatics Software Company 151 QPS Acquires Xendo to Extend the Company Business in Europe 152 Merck KGaA, Darmstadt Acquires Millipore and Forms New EMD Millipore Division 152 Aptuit Acquires GSK’s Research Operations in Italy 152 Promega and Cellular Dynamics Collaborate to Predict Drug-Induced Cardiotoxicity by Using Stem Cell-Based In Vitro Assays 153 Entelos Signs License Agreement with Pfizer 153 CeeTox Acquires Assets of ADMETRx Inc. 153 BioSeek Inks Alliance with Eisai Co. 154 Ricerca Biosciences LLC Buys MDS Pharma Services 154 Helmholtz Centre for Infection Research (HZI) Spins out InSCREENeX GmbH 155 Gentronix Signs Three Year Contract with GlaxoSmithKline for GreenScreen HC and BlueScreen HC Genotoxicity Assays 155 Evotec Inks Alliance with Active Biotech for HTS 155 Bioseek Entered into a Two-Year Collaboration Agreement with Ono 156 CMA Microdialysis Takes Over DiLab 156 Galapagos NV Acquires Service Operations of Argenta Discovery 156 AB SCIEX Acquires Eksigent Liquid Chromatography Business 157 Shenogen and Chemizon Signs Drug Discovery Collaboration Mainly Focused on Oncology and Endocrine Disorders 157 Danaher Buys AB SCIEX and Molecular Devices 158 Celsis IVT Assigns a New Distributor in China 158 Taconic Sets Up specialized Breeding Unit in Edinburgh and Initiates transADMET Program in Association with CXR 158 Pharmaron Acquires Bridge Laboratories China 159 Asan Medical Center and Chemizon Signs Research Agreement 159 AVANZA Acquires Bridge Pharmaceuticals 159 Covance Inaugurates New Clinical Development Headquarters in South Korea and India in Addition to Office Expansion in Japan and Hong Kong 160 BioTrve Spins-off BIOCIUS Life Sciences 160 JOHCM Private Equity Acquires Celsis International plc 161 PPD Acquires BioDuro 161 Asterand Extends Collaboration Agreement with Bristol-Myers Squibb 161 Aureus Pharma Extends Knowledge Database Agreement with Sanofi-Aventis R&D 162 Roche Signs Agreement with Fluofarma 162 Maxxam Analytics Takes Over Cantest 163 Cerep Presents BioPrint® Evaluation License to Roche 163 ChemDiv’s CDRI Enters into Partnership with Viriom 163 NOTOX Teams Up WITH SRC to Offer Integrated Preclinical Services in India 164 Shanghai ChemPartner and ELARA Pharmaceuticals Elaborate Drug Discovery Cooperation to a New Level 164 Expansion of Agreement between Cellular Dynamics International and Roche Pertaining to existing Cardiotoxicity Screening 164 Asterand Signs Worldwide Research Support Agreement with Lundbeck 165 Cellular Dynamics Extends its Partnership Agreement with Roche on Cardiotoxicity Screening 165 Absorption Systems LP Acquires Stake in Perry Scientific Inc 165 Gentronix Unites with Apredica for Offering Predictive-Toxicology Based Drug Discovery Solutions 166 Cerep Enters Drug Discovery & Lead Optimization Collaboration with Servier 166 Covance Undertakes Studies on Integrated Radiolabeled Clinical Pharmacology 166 Quotient Bioresearch Acquires GE’s Amersham Radiolabelling Services 167 Quotient Bioresearch Acquires Charles River Laboratories’ Edinburgh Clinical Research Facility to Form Quotient Clinical 167 Charles River Acquires PRC for Reinforcing Oncology Service Offerings 168 BioDuro Signs Contract Research Agreement with Roche 168 Cellartis and ReproCELL Enter into Marketing Agreement to facilitate Cardiotoxicity Screening Service using hESC Derived Cardiomyocytes 168 ChemDiv’ ChemRar High Tech Center Acquires Prudentas 168 Lhasa Limited, Leadscope, Molecular Networks GmbH and Multicase Collaborate to form Insilicofirst 169 AstraZeneca Extends Discovery Contract with BioDuro 169 The Hamner and Entelos Signs Partnership Agreement 170 Entelos Signs Agreement with GlaxoSmithKline 170 Advancell Signs Agreement with ADMEcell for sales development of Cacoready™ 170 ACD/Labs and Pharma Algorithms Merge 171 Solvay Inks Alliance with ChemDiv to Offer Integrated Research Solutions 171 Gene Logic Enters into Agreement with Genstruct 171 FDA Signs Agreement with Entelos to Forecast Cardiovascular Adverse Events 172 Quotient Bioscience Acquires Pharmaceutical Profiles and Elaborates Metabolic Sciences Services Offerings 172 HTG Teams Up with HC-LITT 173 Applied Biosystems and Invitrogen Merge to Form Life Technologies 173 Pfizer and WuXi PharmaTech in New Collaboration Agreement 174 Roche Enters into Collaboration Relating to ADMETRx’s Multicriteria Decision-Making Solution 174 BioTrove and Agilent Technologies Sign another Agreement giving BioTrove an Access to Agilent’s Mass Spectrometry Instruments 174 BioTrove Enters into an Exclusive Partnership with BD for Improving Effectiveness of Existing Drug Research Analysis Services 175 Charles River Buys MIR Preclinical Services 176 Sekisui America Corporation Acquires XenoTech, L.L.C. 176 Gentronix Join Forces with Abcellute to Enhance Genotoxicity Screening 176 Thermo Fisher Scientific Acquires Affinity BioReagents 177 GVK BIO and Wyeth Pharmaceuticals Signs Drug Discovery Agreement 177 MDS Analytical Technologies/Applied Biosystems Signs an Agreement with BioTrove 177 Pharmasafe in Distribution Agreement for Noraymet ADME software with NorayBio 178 Covance and WuXi PharmaTech in Joint Venture to Provide World-Class Preclinical Services in China 178 Advion BioServices to Increase Investment in Thermo Scientific’s Watson Laboratory Information Management System for Expanding Market Share in Bioanalytical Services 179 Cerep and PerkinElmer in Partnership Agreement for Custom Drug Discovery Solutions 179 Panasonic and Kalypsys to Commercialize HTS System in Collaboration in North America 180 Entelos in Research Agreement with Eli Lilly 180 XenoBiotic Laboratories, Inc. Enters into a Joint Venture with Singapore Mainboard-listed C&O Pharmaceutical Technology (Holdings) Limited 180 Agilent Technologies and Accelrys’ New OEM Agreement Increases their Areas of Cooperation 181 Azopharma Buys Analytical Development Corp. 181 Nimbus Alters its Name to Sovicell and Launches New Website 182 Ono and Evotec in New Fragment-Based Drug Discovery Agreement 182 Genedata and Bayer Expand Research Informatics Partnership 183 Cellartis and Pfizer in Research Collaboration for Development of Screening System to Detect Human Toxicity 183 Science Applications International Corporation Selects Cerep for Profiling Work on Drugs being investigated for treating Spinal Muscular Atrophy 183 Argenta Discovery Enters into Collaboration Agreement with Antisoma 184 Apptec Laboratory Services acquired by WuXi Pharmatech, a Chinese Contract Research Organization 184 Digilab Concludes acquisition of MAIA Scientific and Genomic Solutions 184 Gene Logic Divests Genomics Assets and Changes Corporate Identity 185 Chemdiv Extends Partnership Agreement with NMSI 185 Medivir Gives New Structure to Drug Discovery 186 Entelos, Inc. Agrees to Acquire Iconix Biosciences, Inc. 186 Cerep Sells Hesperion AG Business to Averion International 186 BioFocus DPI Brings Further Advancement to ADME Optimization Services 187 Symyx Technologies Closes Acquisition of MDL Information Systems 188 Simulations Plus Signs Research Agreement with Enslein 188 Acquisition of InVitro Technologies Allows Celsis to offer ADME-Tox Services 188 Gene Logic Enters into Alliance with FDA 189 Gene Logic Enters into Alliance with Solvay Pharmaceuticals to Trace New Development Channels for Multiple Clinical Drug Candidates 189 Amgen Concludes Ilypsa Acquisition 190 Waters Corporation Signs Collaborative Agreement with Umetrics AB 190 TetraQ Gains GLP Status for ADME Laboratory from NATA 190 TIBCO Acquires Spotfire Holdings 191 Waters Corporation to Collaborate with Dotmatics Limited 191 Aureus Pharma Partners with MDL® Isentris® Alliance 191 Galapagos Enters into Alliance with AstraZeneca for Novel Drug Discovery 192 Galapagos Collaborates with Ono Pharmaceutical 192 Lexicon Genetics Adopts New Corporate Identity 192 Avista Capital Acquires BioReliance Corporation 193 VASTox plc Acquires Dextra Laboratories and DanioLabs 193 Takeda Pharmaceutical Acquires Paradigm Therapeutics Limited 194 MDS Acquires Entire Stake in MDC 194 Thermo Fisher Scientific Acquires Cohesive Technologies 195 Qualyst and InterMune in B-CLEAR® Technology Licensing Deal 196 LION Bioscience Adopts New Identity 196 PerkinElmer Acquires Euroscreen Products and Evotec Technologies 196 3.9 Major Product Introductions/Developments in ADME/Tox Market 197 Simulations Plus Unveils Version 7.0 of ADMET Predictor 197 Simulations Plus Unveils ADMET Predictor™ 6.5 197 CompuDrug Introduces New Integrated Research Management System, the Laboratory Manager Plus 197 Accelrys Develops Process Management and Compliance Suite 197 BioReliance In-Licenses Rights to Big Blue® Colonies and Cell Lines from Agilent 198 Xceleron Teams Up with Kinetigen to Simplify and Advance Phase I Clinical Investigations 198 Hamner Institutes for Health Sciences Publicizes Joint Biology Initiative 199 Medicilon Inks Alliance with RILD 199 WuXi PharmaTech Joins Forces with PRA to Provide Broad Portfolio of Clinical Research Services in China 199 GE Healthcare Sublicenses Cellular Dynamics International’s Cellular Assay Patents 200 BioSeek Granted New Five-Year Contract from EPA ToxCast™ Program 200 AB SCIEX and Phytronix Improve High-Throughput Pharmaceutical Application 201 Celerion Receives Full Accreditation from AAHRPP 201 Genedata and Insilico Biotechnology Agrees to Integrate Industrial Biotechnology Platforms 202 PerkinElmer and TIBCO Software Enters into Strategic Alliance for TIBCO Spotfire® Data Visualization and Discovery in Specific Scientific Research & Development Markets 202 AB SCIEX Improves Proteomics Research with the Latest Eksigent Nano L C System 202 PharmaOptima LLC Completes Expansion 203 Woodland Oncology Services in Association with SBH Sciences Launches Preclinical Oncology Services 203 CeeTox and Cellular Dynamics Collaborates to Offer Predictive In-vitro Test for Cardiotoxicity Utilizing Human iPSC-derived Cells 203 Enamine Unites with MRC LMB and IOCB for Discovering Novel Rhomboid Protease Inhibitors as Potential Drugs 204 Celerion Expands State-Of-The Art ADME Suite in its Nebraska Facility 204 AB SCIEX Extends UHPLC Solutions Range with the Introduction of Eksigent Ekspert™ ultraLC 100 and 100-XL Systems as well as Eksigent ekspert™ microLC 200 System 205 AB SCIEX Unveils new AB SCIEX 4500 Series 205 Optibrium Launches New Version of its StarDrop™ platform 206 Quotient Enhances the new LabLogic Software 206 Cyprotex Expands US Facility 206 Caliper Launches Drug Safety Prediction and Oncology Research Platform 207 Cyprotex Enhances Cloe PK Software 207 Almac Launches rapid™ 207 LabLogic introduces Version 6 of Debra LIMS for ADME studies 207 New DNA Sequencing Panel for ADME Research Released by RainDance Technologies and Ambry Genetics 208 ACD/Percepta, a new ADME software from ACD/Labs 209 Highly Effective DNA Sequencing Set Introduced by Ambry Genetics and RainDance Technologies for Research in ADME 209 Optibrium Launches StarDrop 5.1 with Apple Mac Compatibility for Enhanced Drug Discovery 210 iPLEX® ADME PGx is a New Panel from Sequenom for MassARRAY® System 210 Cyprotex Introduces Breakthrough Genomic ADME Service (gADME™) 211 AB SCIEX Extends Eksigent Chip Column Family for Nano and Micro LC Proteomics Analysis 211 Cyprotex Adds High Content Screening in Vitro Micronucleus Test 212 ActivityBase 8.0 Delivers Increased Personal Productivity and Reduced Administration 212 Promega Launches Mitochondrial ToxGlo Assay for Identification of Mitochondrial 213 Puracyp and Promega Combines Cell Lines and Assay Systems for Complete Solution for Drug Developers 213 Covance Widens Drug Metabolism Service Offerings 213 Asterand Licenses and Launches New 3-D Human Cell from Capsant 214 Absorption Systems’ Novelty in Drug Metabolism and Metabolite ID Leads to Patent Application 214 HD Biosciences Introduces Medicinal Chemistry for SAR Focused R&D Services 214 Advion BioServices Inaugurates Midwest Drug Discovery and Metabolism Center of Excellence 215 Pharsight Launches Phoenix® Software for Drug Development 215 SimuGen Launches HT-X Drug Screening Programmes 216 Entelos Successfully Gained US Patent for “Predictive Toxicology for Biological Systems” 216 Gene Logic Introduces Novel ASCENTA 4.0 217 Cyprotex Revalidates CellCiphr™ Toxicity Panels 217 Sigma Life Science Generates Globally First Knock-in Rats Utilizing Zinc Finger Nuclease Technology 218 Lhasa Introduces New Zeneth System 218 Supercomputing Research for Drug Discovery 218 ADME LIMS to Accelerate Data Reporting at QPS 219 Bio-Rad Achieves Advances in Infrared, Raman, and Polymer Spectral Interpretation 219 NOTOX Undertakes Repeated Dose Toxicity Studies in Juvenile Beagle Dogs 220 Charles River Introduces the Gentronix BlueScreen HC Genotoxicity Screening Test 220 BIOCIUS Life Sciences Expands New ADME Assay Analysis Based Contract Research Service 220 Cyprotex Launches Cloe Knowledge for Researchers 220 Simulations Introduces GastroPlus™ Version 7.0 221 Simulations Unveils MedChem Studio 221 New York State Approves CLIA DNA Test of Genelex 221 Transatlantic Adopts Common Radio-labelled ADME Platform 222 NIEHS Installs Provantis® Preclinical Software Solution 222 Cyprotex Introduces Cyprotox®, an In Vitro Toxicology Services 222 Simulations Plus Introduces Advanced Version of ADMET Predictor 223 GeneGo Launches ToxHunter Tools for Systems Toxicology Research 223 Simcyp Introduces Advanced Version of Proprietary Simulator 224 Absorption System Launches Express Plus ADME Assays 224 Pipeline Pilot™ 8.0 Launched by Accelrys 224 Agilent & BIOCIUS Launch High-Throughput, RapidFire® Accurate Mass Solution for Drug Discovery 225 Bruker Launches High Performance Mass Spectrometry Systems and Applications for Complete Bio-therapeutics Analysis 225 Optivia Introduces OptiDDITM Suite 226 Covance Sets Up an Advanced Discovery & Translational Services Unit 226 Thermo Fisher Scientific Launches New Biological Assessment Cartridges 227 Absorption Systems Incorporates Thermo Fisher’s LTQ Orbitrap XL 227 Lablogic Introduces New Version of LIMS 228 Caliper Life Sciences Introduces Quantum FX microCT System - a New Modality for Pre-Clinical Imaging 228 Illumina Launches VeraCode(R) ADME Core Panel 228 MCM Employs Provantis Preclinical Software Solution 229 Cellartis Launches Novel 2D Cardiomyocyte Product 229 Quotient Bioresearch Expands In Vitro Services 229 Entelos and RegeneMed Launches iToxFX to Facilitate the Prediction of New Drugs Safety 230 Sigma-Aldrich to Offer Knockout Rats for ADME/Tox 230 SIGMA Launches World's First Suite of Knockout Rats for ADME/Tox Applications 231 Advion BioSystems Introduces a New LESA Sample Analysis System 231 Gentronix Introduces Bluescreen HC and Expands Comet Assay Testing Based Services 231 PharmaDiagnostics Launches SoPRano™ Range of Screening Products and Services 232 LGC Standards Adds Extra Drug Discovery Tools 232 Hudson Robotics Launches New ADME-Tox Screening System 233 XBL Advances QWBA and Cryo-Imaging Services 233 New Drug Metabolism Assays Launched by Absorption Systems 233 XenoTech Launches CryostaX™, an Innovative Single-Freeze Source for Human Hepatocytes 234 Cellumen Discovers in vitro Rat Hepatocyte Early Safety Assessment Panel for DILI predictivity 234 NiKem Obtains Italian GLP Certification for Bio-Analysis Facility 234 BioWisdom Introduces Safety Intelligence Program (Version 3.0) 235 Advion BioServices enhances the LC/MS Biomarker Service Unit 235 Aureus Pharma Launches DDI Predict 2009 Edition 236 Expansion of Cytotoxic and ADME Services by Wolfe Laboratories 236 RapidFire® Granted CE Mark, First System in Europe Installed at Boehringer Ingelheim 236 Eksigent Declares Major Development for HPCL Manufacturing and Service 237 Covance expands Service Capacity and Expertise for Metabolite Identification 237 Advancell Launches Cellular Reagent Isocyp-Tox™, for Hepatic Toxicity Prediction 238 New Mass Spectrometry Solution Cliquid® MPX™-2 Launched by Applied Biosystems and MDS Analytical Technologies 238 Thermo Fisher Scientific Launches Thermo Scientific Cellomics ToxInsight Solution for In Vitro Toxicity Testing 238 BD Biosciences Releases BD UltraPool™ HLM 150 Reagent 239 Standardized and Cost-Efficient Drug Metabolizing Enzymes and Transporters (DMET) Analysis Services Launched Globally by Cogenics 239 BioTrove Launches RapidFire 300 for In-vitro ADME Screening 240 TTP LabTech Launches Acumen® eX3 240 XBL Enhances Key Services 240 Nikem Expands ADMET and In-vivo Assay Capabilities 241 Millipore Corporation and CXR Biosciences Launches Toxicity Reporter Assay Panel 241 Applied Biosystems/MDS Analytical Technologies Launches New Version of DiscoveryQuant™ Software 241 BioFocus Strengthens ADME/PK Laboratory Bioanalytical Capabilities 242 BioWisdom Unveils Version 2 of KnowledgeScan and contracts with BTG to Provide to Enhanced Solutions 242 Cresset BioMolecular Discovery Releases FieldStere 243 Bio-Rad Incorporates Automatic Filtering of NMR Spectra (AFNS) of University of Wisconsin-Madison in to KnowItAll® Metabolomics Software 243 Eksigent Launches ExpressHT™-Ultra HPLC System 243 Bio-Rad Launches Latest Infrared and UV-Vis Spectral Databases 244 Aptuit Introduces Program to Accelerate Early Stage Drug Development 244 Thermo Fisher Scientific Launches ToxSpec Analyzer 244 Simcyp Introduces Virtual ‘Lab Rat’ 245 PerkinElmer Launches GMP Compliant Radiolabeling Services for Drug Candidate Screening 245 BioFocus DPI Opts for BioBook to Manage ADME Data 246 ADME LIMS Suitable for Unlabelled Compound Data 246 Assay Depot Introduces Online Drug Discovery Services 246 Ariadne Introduces Pathway Studio® Version 6 247 FDA Licenses ADMET Predictor™ from Simulations Plus 247 Leadscope Launches FDA QSAR Toxicity Models 247 US Patent Grants for Gene Expression Based Liver Toxicity Screening Test 248 ADME LIMS to Monitor Sampling Time Deviations 248 New Technology Employed in ADMET Predictor™ 3.0 for Molecular Descriptors 248 CXR Biosciences and Millipore Corporation Launch New Antibody Panel 249 Xceleron’s New Research Laboratory in Maryland, USA Starts Operations 249 Gwathmey Launches Cardionomics™ Services for Preclinical Cardiac Safety Screening of Drug Candidates 250 Cyprotex Launches New Catalogue for Experimental and Predictive ADME and PK Services 250 Simcyp Launches Version 8.0 of Simcyp Population-based ADME Simulator 251 Cyprotex Launches Cloe® Select 251 Simcyp Launches Latest Version of Pediatric ADME Simulator 251 BioFocus DPI Introduces ADME/PK Laboratory Services and StarDrop™ Software Solution 252 Novel Assay-Specific Human Liver Microsomes Launched by Celsis In Vitro Technologies 252 Abacalab Launches Chemistry Labacus (R) Version 2.1 253 Pharma Algorithms Releases New ADME Boxes Version 4.0 253 Simulations Plus Releases New Important Upgrade of ClassPharmer™ Software 253 Applied Biosystems and Sciex Jointly Launch the New Cliquid™ Drug Screen and Quant Software for Application in Routine Forensic Toxicology 254 BioReliance Introduces Novel Genotoxicity Screening Service 254 Caliper Life Sciences Introduces CDAS for Offering Complete Drug Discovery and Development Services 255 Simulations Plus Introduces New DNA Mutation Predictor 256 Simulations Plus Launches ADMET Predictor™ Version 2.3 256 Pharma Algorithms Announces ToxBox Version 2.0 256 Aureus Pharma Introduces New Tool to Identify Risks of Drug-Drug Interactions 257 DTEx™ - New technology for Gene Expression Profiling for Drugs 257 Strand Introduces New Platform for In Silico Lead Optimization 258 NMS Introduces the New Brand Accelera 258 3.10 In Vivo ADME/Tox – An Ever Growing Technology 259 Global In Vivo ADME/Tox Market Analysis 259 Exhibit 21. In Vivo ADME/Tox Technologies– Global Market Estimations and Predictions (2005-2020) for North America, Europe, Asia-Pacific, and Rest of World in US$ Million 260 Exhibit 22. In Vivo ADME/Tox Technologies – Global Market Shares (2010,2015 & 2020) for North America, Europe, Asia-Pacific, and Rest of World 261 Exhibit 23. List of Global In Vivo ADME/Tox Companies 261 3.10.2 North American In Vivo ADME/Tox Market Analysis 263 Exhibit 24. In Vivo ADME/Tox Technologies– North American Market Estimations and Predictions (2005-2020) for United States and Canada in US$ Million 263 Exhibit 25. In Vivo ADME/Tox Technologies – North American Market Shares (2010, 2015 & 2020) for United States, and Canada 264 3.10.2 (1) United States In Vivo ADME/Tox Market 264 3.10.2 (1I) Canadian In Vivo ADME/Tox Market 264 3.10.3 European In Vivo ADME/Tox Market Analysis 265 Exhibit 26. In Vivo ADME/Tox Technologies– European Market Estimations and Predictions (2005-2020) for UK, Germany, France, Sweden, Finland, Italy, Russia and Rest of Europe in US$ Million 265 Exhibit 27. In Vivo ADME/Tox Technologies – European Market Shares (2010, 2015 & 2020) for UK, Germany, France, Sweden, Finland, Italy, Russia and Rest of Europe 266 3.10.3 (1) United Kingdom In Vivo ADME/Tox Market 266 3.10.3 (II) German In Vivo ADME/Tox Market 266 3.10.3 (III) French In Vivo ADME/Tox Market 266 3.10.3 (IV) Swedish In Vivo ADME/Tox Market 266 3.10.3 (V) Finnish In Vivo ADME/Tox Market 267 3.10.3 (VI) Italian In Vivo ADME/Tox Market 267 3.10.3 (VII) Russian In Vivo ADME/Tox Market 267 3.10.4 Asia-Pacific In Vivo ADME/Tox Market 268 Exhibit 28. In Vivo ADME/Tox Technologies– Asia-Pacific Market Estimations and Predictions (2005-2020) for Japan, China, India, Australia, South Korea and Rest of Asia-Pacific in US$ Million 268 Exhibit 29. In Vivo ADME/Tox Technologies – Asia-Pacific Market Shares (2010, 2015 & 2015) for Japan, China, India, Australia, South Korea and Rest of Asia-Pacific 269 3.10.4 (1) Japanese In Vivo ADME/Tox Market 269 3.10.4 (II) Chinese In Vivo ADME/Tox Market 269 3.10.4 (III) Indian In Vivo ADME/Tox Market 269 3.10.4 (IV) Australian In Vivo ADME/Tox Market 269 3.10.4 (V) South Korean In Vivo ADME/Tox Market 269 3.10.5 Rest of World In Vivo ADME/Tox Market 270 Exhibit 30. In Vivo ADME/Tox Technologies– Rest of World Market Estimations and Predictions (2005-2020) for Brazil, South Africa, Israel, and Other Countries in US$ Million 270 Exhibit 31. In Vivo ADME/Tox Technologies– Rest of World Market Shares (2010, 2015 & 2020) for Brazil, South Africa, Israel, and Other Countries 271 3.10.5 (1) Brazilian In Vivo ADME/Tox Market 271 3.10.5 (III) South African In Vivo ADME/Tox Market 271 3.10.5 (II) Israeli In Vivo ADME/Tox Market 271 3.11 In Vitro ADME/Tox – An Emerging Technology 272 3.11.1 Global In Vitro ADME/Tox Market Analysis 272 Exhibit 32. In Vitro ADME/Tox Technologies – Global Market Estimations and Predictions (2005-2020) for North America, Europe, Asia-Pacific, and Rest of World in US$ Million 273 Exhibit 33. In Vitro ADME/Tox Technologies – Global Market Shares (2010, 2015 & 2020) for North America, Europe, Asia-Pacific, and Rest of World 274 Exhibit 34. List of Major Global In Vitro ADME/Tox Companies 274 3.11.2 North American In Vitro ADME/Tox Market Analysis 277 Exhibit 35. In Vitro ADME/Tox Technologies– North American Market Estimations and Predictions (2005-2020) for United States and Canada in US$ Million 277 Exhibit 36. In Vitro ADME/Tox Technologies – North American Market Shares (2010,2015 & 2020) for United States, and Canada 278 3.11.2 (I) United States In Vitro ADME/Tox Market 278 3.11.2 (I1) Canadian In Vitro ADME/Tox Market 278 3.11.3 European In Vitro ADME/Tox Market 279 Exhibit 37. In Vitro ADME/Tox Technologies– European Market Estimations and Predictions (2005-2020) for UK, Germany, France, Sweden, Finland, Italy, Russia and Rest of Europe in US$ Million 279 Exhibit 38. In Vitro ADME/Tox Technologies – European Market Shares (2010, 2015 & 2020) for UK, Germany, France, Sweden, Finland, Italy, Russia and Rest of Europe 280 3.11.3 (1) United Kingdom In Vitro ADME/Tox Market 280 3.11.3 (II) German In Vitro ADME/Tox Market 280 3.11.3 (III) French In Vitro ADME/Tox Market 280 3.11.3 (IV) Swedish In Vitro ADME/Tox Market 280 3.11.3 (V) Finnish In Vitro ADME/Tox Market 281 3.11.3 (VI) Italian In Vitro ADME/Tox Market 281 3.11.3 (VII) Russian In Vitro ADME/Tox Market 281 3.11.4 Asia-Pacific In Vitro ADME/Tox Market 282 Exhibit 39. In Vitro ADME/Tox Technologies– Asia-Pacific Market Estimations and Predictions (2005-2020) for Japan, China, India, Australia, South Korea and Rest of Asia-Pacific in US$ Million 282 Exhibit 40. In Vitro ADME/Tox Technologies – Asia-Pacific Market Shares (2010, 2015 & 2015) for Japan, China, India, Australia, South Korea and Rest of Asia-Pacific 283 3.11.4 (I) Japanese In Vitro ADME/Tox Market 283 3.11.4 (II) Chinese In Vitro ADME/Tox Market 283 3.11.4 (III) Indian In Vitro ADME/Tox Market 283 3.11.4 (IV) Australian In Vitro ADME/Tox Market 283 3.11.4 (V) South Korean In Vitro ADME/Tox Market 283 3.11.5 Rest of World In Vitro ADME/Tox Market 284 Exhibit 41. In Vitro ADME/Tox Technologies– Rest of World Market Estimations and Predictions (2005-2020) for Brazil, South Africa, Israel and Other Countries in US$ Million 284 Exhibit 42. In Vitro ADME/Tox Technologies– Rest of World Market Shares (2010, 2015 & 2020) for Brazil, Israel, South Africa, and Other Countries 285 3.11.5 (1) Brazilian In Vitro ADME/Tox Market 285 3.11.5 (III) South African In Vitro ADME/Tox Market 285 3.11.5 (II) Israeli In Vitro ADME/Tox Market 285 3.12 In Silico ADME/Tox – The Fastest Growing Technology 286 3.12.1 Global In Silico ADME/Tox Market 286 Exhibit 43. In Silico ADME/Tox Technologies – Global Market Estimations and Predictions (2005-2020) for North America, Europe, Asia-Pacific, and Rest of World in US$ Million 287 Exhibit 44. In Silico ADME/Tox Technologies – Global Market Shares (2010, 2015 & 2020) for North America, Europe, Asia-Pacific, and Rest of World 288 Exhibit 45. List of Major Global In Silico ADME/Tox Companies 288 3.12.2 North American In Silico ADME/Tox Market Analysis 289 Exhibit 46. In Silico ADME/Tox Technologies– North American Market Estimations and Predictions (2005-2020) for United States and Canada in US$ Million 289 Exhibit 47. In Silico ADME/Tox Technologies – North American Market Shares (2010, 2015 & 2020) for United States, and Canada 290 3.12.2 (1) United States In Silico ADME/Tox Market 290 3.12.2 (II) Canadian In Silico ADME/Tox Market 290 3.12.3 European In Silico ADME/Tox Market 291 Exhibit 48. In Silico ADME/Tox Technologies– European Market Estimations and Predictions (2005-2020) for UK, Germany, France, Sweden, Finland, Italy, Russia and Rest of Europe in US$ Million 291 Exhibit 49. In Silico ADME/Tox Technologies – European Market Shares (2010, 2015 & 2020) for UK, Germany, France, Sweden, Finland, Italy, Russia and Rest of Europe 292 3.12.3 (I) United Kingdom In Silico ADME/Tox Market 292 3.12.3 (II) German In Silico ADME/Tox Market 292 3.12.3 (III) French In Silico ADME/Tox Market 292 3.12.3 (IV) Swedish In Silico ADME/Tox Market 292 3.12.3 (V) Finnish In Silico ADME/Tox Market 293 3.12.3 (VI) Italian In Silico ADME/Tox Market 293 3.12.3 (VII) Russian In Silico ADME/Tox Market 293 3.12.4 Asia-Pacific In Silico ADME/Tox Market 294 Exhibit 50. In Silico ADME/Tox Technologies– Asia-Pacific Market Estimations and Predictions (2005-2020) for Japan, China, India, Australia, South Korea and Rest of Asia-Pacific in US$ Million 294 Exhibit 51. In Silico ADME/Tox Technologies – Asia-Pacific Market Shares (2010, 2015 & 2020) for Japan, China, India, Australia, South Korea and Rest of Asia-Pacific 295 3.12.4 (I) Japanese In Silico ADME/Tox Market 295 3.12.4 (II) Chinese In Silico ADME/Tox Market 295 3.12.4 (III) Indian In Silico ADME/Tox Market 295 3.12.4 (IV) Australian In Silico ADME/Tox Market 295 3.12.4 (V) South Korean In Silico ADME/Tox Market 295 3.12.5 Rest of World In Silico ADME/Tox Market 296 Exhibit 52. In Silico ADME/Tox Technologies– Rest of World Market Estimations and Predictions (2005-2020) for Brazil, South Africa, Israel, and Other Countries in US$ Million 296 Exhibit 53. In Silico ADME/Tox Technologies– Rest of World Market Shares (2010, 2015 & 2020) for Brazil, South Africa, Israel, and Other Countries 297 3.13 Related Technologies 298 3.13.1 Laboratory Information Management Systems 298 Exhibit 54. Laboratory Information Management System (LIMS) – Global Market Estimations and Predictions (2005-2020) in US$ Million 298 3.13.2 High Throughput Screening 299 18.104.22.168 Global HTS Market 299 Exhibit 55. High Throughput Screening (HTS) – Global Market Estimations and Predictions (2005-2020) in for United States, Europe, Asia-Pacific, Canada and Rest of World US$ Million 300 Exhibit 56. High Throughput Screening (HTS) – Global Market Shares (2010, 2015 & 2020) for North America, Europe, Asia-Pacific and Rest of World 301 US Market for High Throughput Screening (HTS) 301 Canadian Market for HTS 301 European Market for HTS 301 Asia-Pacific Market for HTS 301 22.214.171.124 Global HTS Products Market 302 Exhibit 57. HTS Products – Global Market Estimations and Predictions (2005-2020) in US$ Million 302 126.96.36.199 Global Market for Re-Screening of Hits 303 Exhibit 58. Re-Screening of Hits – Global Market Estimations and Predictions (2005-2020) in US$ Million 303 188.8.131.52 Global Market for HTS Services and Consumables 304 Exhibit 59. HTS Services and Consumables – Global Market Estimations and Predictions (2005-2020) in US$ Billion 304 184.108.40.206 Global Market for HTS Services and Cell Based Consumables 305 Exhibit 60. HTS Services and Cell Based Consumables – Global Market Estimations and Predictions (2005-2020) in US$ Billion 305 220.127.116.11 Global Spending on HTS for Lead Discovery 306 Exhibit 61. Spending on HTS for Lead Discovery – Global Market Estimations and Predictions (2005-2020) for United States, Europe, and Rest of World in US$ Billion 306 18.104.22.168 US Spending on HTS for Lead Discovery 307 Exhibit 62. Spending on HTS for Lead Discovery- United States Market Estimations and Predictions (2005-2020) in US$ Billion 307 22.214.171.124 European Spending on HTS for Lead Discovery 308 Exhibit 63. Expenditure on HTS for Lead Discovery – European Market Estimations and Predictions (2005-2020) in US$ Billion 308 3.13.3 Cell Based Assays 309 126.96.36.199 Global Market for Cell Based Assays 309 Exhibit 64. Cell-Based Assays – Global Market Estimations and Predictions (2005-2020) for United States, Europe, Asia-Pacific, Canada and Rest of World in US$ Million 310 Exhibit 65. Cell-Based Assays – Global Market Shares (2010,2015 & 2020) for United States, Europe, Asia-Pacific, Canada and Rest of World 311 US Market for Cell Based Assays 311 Canadian Market for Cell Based Assays 311 European Market for Cell Based Assays 311 188.8.131.52 Global Pharmaceutical Cell Based Screening Market 312 Exhibit 66. Pharmaceutical Cell-Based Screening – Global Market Estimations and Predictions (2005-2020) in US$ Billion 312 3.13.4 Global Drug Discovery Market 313 184.108.40.206 Global Drug Discovery Expenditure 313 Exhibit 67. Drug Discovery Expenditure – Global Market Estimations and Predictions (2005-2020) in US$ Billion 314 220.127.116.11 US Market for Pharma Contract Research 315 Exhibit 68. Pharmaceutical Contract Research – United States Market Estimations and Predictions (2005-2020) in US$ Billion 315 Exhibit 69. Number of Approved Drugs in the United States as of 2013 316 18.104.22.168 European Market for Drug Discovery 317 Exhibit 70. Drug Discovery – European Market Estimations and Predictions (2005-2020) in US$ Billion 317 22.214.171.124 European Market for Drug Discovery Outsourcing 318 Exhibit 71. Drug Discovery Outsourcing – European Global Market Estimations and Predictions (2005-2020) in US$ Billion 318 126.96.36.199 European Market for Nanotechnology Based Drug Discovery 319 Exhibit 72. Drug Discovery Based on Nanotechnology – European Market Estimations and Predictions (2005-2020) in US$ Billion 319 188.8.131.52 Asia-Pacific Market for Drug Discovery 320 Drug Discovery Scenario in Asia-Pacific 320 Exhibit 73. Drug Discovery– Asia-Pacific Market Estimations and Predictions (2005-2020) in US$ Billion 321 184.108.40.206 Asia-Pacific Market for Pharma CROs 322 Exhibit 74. Pharmaceutical Contract Research Organization – Asia-Pacific Market Estimations and Predictions (2005-2020) in US$ Billion 322 3.13.5 Global Biotech Industry at a Glance 323 220.127.116.11 Major Research Areas in Biotechnology 324 Exhibit 75. Global Biotechnology Industry (2012): Percentage Breakdown of Major Research Areas 324 18.104.22.168 Canadian Market for Biotech R&D 325 Exhibit 76. Biotechnology R&D Expenditure – Canadian Market Estimations and Predictions (2005-2020) in US$ Billion 325 22.214.171.124 European Biotechnology Market 326 Exhibit 77. Biotechnology R&D Expenditure – European Market Estimations and Predictions (2005-2020) in US$ Billion 327 3.14 ADME/Tox Technologies – Market Outlook 328 Key Market Challenges 328 Other Side of the Coin 329 Key Market Drivers 330 4. PRODUCT/TECHNOLOGY RESEARCH 331 4.1 Introduction 331 ADME/Tox – The Basics 331 Absorption 332 Distribution 332 Metabolism 332 Excretion 332 Toxicity 333 Factors Determined by ADME/Tox 333 ADME/Tox Properties are Determined by - 333 The Increasing Need to Predict ADME/Tox Profiles 334 Preclinical ADME/Tox Evaluation Tools 335 Some of the Current Evaluation Tools for ADME/Tox in Use Include – 335 Preclinical ADME/Tox Tools are generally validated for – 336 4.2 ADME/Tox – Essence of Pharmaceutical Industry 337 Drug Development - An Overview 338 Origin and Development of New Chemical Entity (NCE) 338 Process of Drug Development 339 Target Identification 339 Target Validation 339 Lead Identification 339 Technologies for Lead Generation 340 Common Technologies for Lead Generation Include - 340 Lead Optimization 340 Preclinical Trials 340 Technologies for Preclinical Development of Drug Candidates 341 Clinical Trials 341 Phase I 341 Phase II 341 Phase III 342 Exhibit 78. Drug Development Cost - Estimations and Predictions (2005-2020) in US$ Million 342 Major hurdles in drug development process are: 343 Stages of Drug Development 344 Exhibit 79. Critical Path for a Drug to Enter Clinical Trials 344 Improved Technology Infrastructure Increases Potential of Manufacturing Efficiency 345 Exhibit 80. Estimated Time Required for Development of Drugs by Primary Indication (In Years) 346 4.3 ADME/Tox in Drug Discovery Process 347 Factors Influencing Drug Approval Rates 347 Ideally, a successful DMPK drug - 347 Estimating Potential R&D Efficiency Gains from an Improved Technology Infrastructure 348 Reasons for the Decline in Success Rates 348 Exhibit 81. Reasons for Drug Failure in Clinical Trials Phase I – III 349 4.4 ADME/Tox Methods 350 Predictive Technologies 350 Overlapping of Predictive ADME/Tox Technologies 350 Applications by Technology 350 Exhibit 82. Overlapping of Predictive ADME/Tox Technology Applications across Various Stages of Drug Discovery 350 Importance of In Vivo Tests 351 Exhibit 83. In Vivo ADME/Tox Methods 351 Modern In Vivo ADME/Tox Models 351 Zebrafish 351 Rodent Models 352 Drosophila 352 C.elegans 352 Conventional In Vivo ADME/Tox Models 352 Radiolabels 352 Cassette Dosing 352 Semi Simultaneous Dosing 352 Why do we Need Animals for Trials? 352 In Vitro ADMET 353 In Vitro Assays 353 Veterinary In Vitro Testing 353 Exhibit 84. Veterinary In Vitro Testing Technologies – Global Market Estimations and Predictions (2005-2020) in US$ Million 354 In Vitro Applications for Drug Discovery and Development 355 Human and Animal Metabolism 355 Permeation Studies 355 Other ADME Services 355 Exhibit 85. In Vitro ADME/TOX Methods 355 Examples of Human in Vitro ADME/Tox Assays Include 356 Biological Assay Systems for the Evaluation of Cytochrome P450 Enzyme Isoforms 357 In Silico ADMET 357 In Silico Applications along Preclinical Stages 358 In Silico Predictive Models 358 Broad Segmentation of In Silico Technology 358 Analysis by Segment 359 Exhibit 86. In Silico ADME/Tox – Global Value Market Estimations and Predictions (2005-2020) for Organ and Tissue Cells, Cellular Networks, and Whole Cells in US$ Million 359 Applications of In Silico Models in Drug Discovery Process 360 Potential Applications of In Silico Technology 360 Prediction of In Silico Profiles by Metabolic Behavior 360 In Silico Technologies – Market Scenario 360 Prospects 360 Constraint 360 Related Technologies 361 Screening Technologies 361 The various types of screening technologies include 361 High Throughput Screening 361 Primary Screening 362 Secondary Screening 363 Biochemical Assays 364 Cell based Assays 364 High Content Screening 364 4.5 Toxicity 364 Toxicity – An Overview 364 Exhibit 87. Percentage of Toxicities Leading to Drug Failures in Clinical Trials (Phase I-III) 365 Toxicology - Reason for Drug Failure 365 Preclinical Toxicology 367 Predictive Toxicology 367 Methods and Challenges Involving Predictive Toxicology in Drug Discovery & Development 367 “Rule of Five” 368 ADME/Tox Models (Statistical Significance / Mechanistic Interpretation) 368 Challenges of ADME/Tox Prediction 369 Determining Factors for Effective Predictive Toxicology in Preclinical Stage 369 Remedial Measures 370 Types of Toxicities 370 Exhibit 88. Common Types of Toxicity Targeted for ADME/TOX Predictive Techniques 370 Hepatotoxicity or Drug Induced Liver Injury (DILI) 371 Metabolism of Drugs 371 Metabolism of Drug in Liver 371 Factors Resulting in Liver Damage 372 Drug Response 372 Future Prospects 373 Cardiotoxicity 373 Diagnosis 373 Cardiovascular Toxicity and QT Prolongation 374 Nephrotoxicity 374 Diagnosis 375 Neurotoxicity 375 Pulmonary Toxicity 376 Diagnosis 377 Pulmonary Toxicity Due to Medicinal Drugs 377 Pulmonary Toxicity Due to Radiation (Radiotherapy) 377 Pulmonary Toxicity Due to Chemical Compounds 377 Pulmonary Toxicity Due to Particulate Matter (cars, industry, etc) 378 Myotoxicity or Muscle Related Diseases 378 Dermatoxicity or Skin Related Allergies 378 Phototoxicity 378 Oculotoxicity 379 Reproductive Toxicity 379 Genotoxicity 380 Ames Testing to Confirm Genotoxicity 380 Genotoxicity and its Serious Impact on Regulatory Agencies 381 Hematotoxicity 381 Carcinogenicity 381 Cytotoxicity 381 Torsades de pointes 382 Exhibit 89. Common Approved In Vitro and In Vivo Procedures 382 Types of Predictive Toxicology 382 Computational Toxicology 382 QSAR 383 In Vitro Toxicology 383 Exhibit 90. Non-animal Methods being Considered for Validation 383 In Vitro Toxicology – Liver Cell Models 383 Tissue Culture Systems Used in In Vitro Toxicology 384 In Vitro Toxicology Applications 384 Genomics in Toxicity Testing 384 Examining Neurotoxicity 385 Alternatives for Animals in Toxicity Testing 386 Exhibit 91. Common Animals Used for ADME and Toxicity Testing 386 Exhibit 92. In vivo Animal Models for Toxicity Tests and their Importance 386 4.6 ADME/TOX and Drug Discovery Technologies 387 Pharmacogenomics 387 Pharmacokinetics 388 LADMET-R and Pharmacokinetics 389 ADME Associated Proteins 390 A – Category 390 D – Category 390 M – Category 390 E – Category 391 Exhibit 93. Classification of Protein Targets by Category 391 Proteomics 392 Bioinformatics 392 Challenges Facing the ADME/Tox Industry 392 4.7 ADME/TOX Technologies – Research Briefs 394 Computing toxic chemicals 394 Faster smarter and cheaper drug discovery 395 Novel drug –screening process gives long sought anti-HIV compounds-Potential drugs acts on target that are not likely to mutate 395 Validation of the Preclinical efficacy of the TB drug target 397 Genomics of ADME 397 The edge of the drug development 397 Pharmacogenetics Testing Provides Way to Decrease Deaths Caused by Drug Toxicity 398 A computer/test tube combination provides the best drug developments results ever 398 Comprehensive study indicating better time frame of a drug remaining in its target (residence time) leads to enhanced therapeutic and diagnostic agents 399 Drug Metabolism Interaction of Enzymes and its Significance to Toxicity and Effectiveness 400 Zebrafish the latest entrant in the drug Development process 400 Novel methods in the development of Functional Hepatocytes explored by Scientists 402 The protocol to eliminate costly missteps in the process of drug development 403 Avoiding Expensive Missteps in Developing Drugs 403 MetaChip introduce rapid and effective toxicity screening protocol for potential drugs 404 5. CORPORATE DIRECTORY 406 6. PATENTS INFORMATION 434
Our library has over 100000 reports on 1000s of topics
Over 100+ Fortune 500 companies rely on us
90,000+ people come to us for insights every month
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.